Reply By Authors

J Urol. 2019 Dec;202(6):1208. doi: 10.1097/01.JU.0000581976.09106.a4. Epub 2019 Sep 5.

Authors

David Margel^{1

2}, Avivit Peer³, Yaara Ber¹, Liat Shavit-Grievink^{1

4}, Tzlil Tabachnik¹, Sivan Sela¹, Guy Witberg⁵, Jack Baniel^{1

2}, Daniel Kedar^{1

2}, Wilhelmina C M Duivenvoorden⁶, Eli Rosenbaum⁴, Jehonathan H Pinthus⁶

Affiliations

¹ Division of Urology, Rabin Medical Center, Petach Tikva, Israel.
² Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
³ Department of Oncology, Rambam Health Care Campus and Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
⁴ Davidoff Cancer Centre, Rabin Medical Center, Petach Tikva, Israel.
⁵ Department of Cardiology, Rabin Medical Center, Petach Tikva, Israel.
⁶ Division of Urology, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.

PMID: 31487209
DOI: 10.1097/01.JU.0000581976.09106.a4

No abstract available

Publication types

Comment

MeSH terms

Cardiovascular Diseases*
Gonadotropin-Releasing Hormone
Humans
Male
Prostatic Neoplasms*

Substances

Gonadotropin-Releasing Hormone